In this article, we will discuss the 8 Best CBD Stocks to Buy Right Now.
The CBD sector is showing signs of entering a more mature and sustainable growth phase. This shift is drawing renewed investor attention to CBD stocks. Industry analysts say the market is transitioning from the speculative boom that followed the 2018 US farm bill into a more disciplined sector driven by consumer demand, product innovation, operational discipline, and improving regulations.
In 2026, the cannabis industry is being defined by consolidation and a shift to sustainable profitability.
The long-term market opportunity remains significant. Grand View Research estimates that the global CBD market could expand from roughly $18.2 billion in 2025 to around $39.7 billion in 2033, reflecting a nearly 10% CAGR. This growth is expected to be driven by rising demand for CBD wellness products, including those targeting sleep, anxiety, and pain problems.
The rapid expansion of newer categories, such as CBD-based beverages, chocolates, gummies, and skincare products, is also fueling industry growth.
The broader cannabis sector sentiment has started to improve following challenges in recent years. Recent industry forecasts from Whitney Economics project a stronger US cannabis market in 2026 as companies consolidate operations and cut costs to focus on improving profitability and cash flow. For investors, many CBD stocks now offer exposure to a rapidly expanding market with substantial long-term growth potential.
That said, this article explores some of the best CBD stocks to buy right now.
Our Methodology
To compile the list of the 8 best CBD stocks to buy right now, we sifted through industry publications and reviewed financial media reports to identify companies that produce and sell cannabidiol (CBD) products. We ended up with more than a dozen stocks in our initial list and applied additional filters to pick out the best. We selected CBD stocks that hedge funds like and have at least 5% upside potential. The hedge fund data was sourced from Insider Monkey’s database as of Q1 2026. Finally, we ranked the stocks based on their price upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best CBD Stocks to Buy Right Now
8. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Stock Upside Potential: 5.86%
Number of Hedge Fund Holders: 48
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the best CBD stocks to buy right now. The stock has gained almost 40% year-to-date, and analysts see more upside in it.
According to Jazz Pharmaceuticals’ Q1 2026 results released on May 5, revenue from CBD-based epilepsy drug Epidiolex rose 15% YoY to $250 million in that quarter. The increase was driven by continued strong demand for Epidiolex, which is used to treat severe forms of epilepsy. Outside the US, Epidiolex is marketed under the Epidyolex brand name.
Jazz has partnered with Nippon Zoki to commercialize Epidyolex in Japan as it works to expand the drug’s market. Epidiolex was Jazz’s second-largest business by revenue contribution in Q1 after the company’s sleep franchise.
Jazz’s consolidated revenue from the various business lines came to $1.1 billion, reflecting an increase of 19% YoY. The company delivered a net income of $293.1 million, compared with a net loss of $92.5 million a year ago.
Looking ahead, Jazz Pharmaceuticals anticipates full-year 2026 revenue of between $4.25 billion and $4.5 billion. The company is advancing its pipeline projects as it seeks to fuel long-term growth.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is a biopharmaceutical company whose programs include cannabinoid therapeutics. Its CBD-based blockbuster drug Epidiolex is used to treat severe epilepsy. The company was founded in 2003 and is based in Ireland.
7. Canopy Growth Corp (NASDAQ:CGC)
Stock Upside Potential: 18.88%
Number of Hedge Fund Holders: 11
Canopy Growth Corp (NASDAQ:CGC) is one of the best CBD stocks to buy right now. On May 7, Canopy Growth Corp (NASDAQ:CGC) announced the expansion of its cannabinoid softgel lineup. This two-fold expansion includes the launch of new pack sizes and the introduction of additional dosing options.
Regarding pack sizes, Canopy Growth has introduced new 30-pack and 90-pack formats of the softgel product. The company said that offering these formats reflect its commitment to improve patient access with targeted, need-stated products.
According to Canopy Growth, its existing 30-pack offering has performed strongly, so it’s building on that strength with the new pack offering. Andrew Bevan, Canopy Growth’s senior vice-president of medical, stated that they are focused on building a portfolio that reflects the feedback from patients and clinics.
So far, the success of the existing 30-pack formats has made the management understand that patients are looking for more value and greater access to cannabinoid formulations. With the expanded lineup, Canopy Growth says it delivers greater flexibility for patient dosing and improves affordability. The company distributes the cannabinoid softgel products through its medical division, Spectrum Therapeutics.
Canopy Growth Corp (NASDAQ:CGC) is a Canadian cannabis company based in Ontario. The company produces and distributes a wide variety of cannabis and hemp products for medical and recreational use. Its portfolio includes various types of hemp-derived CBD products, including gummies, oil drops, and softgels.
6. Cronos Group Inc (NASDAQ:CRON)
Stock Upside Potential: 39.35%
Number of Hedge Fund Holders: 16
Cronos Group Inc (NASDAQ:CRON) is one of the best CBD stocks to buy right now. The stock is up roughly 40% over the past year, and analysts see it rising further over the next 12 months.
On May 11, Cronos Group Inc (NASDAQ:CRON) reported Q1 2026 results that surpassed expectations. Net revenue jumped 40% YoY to a record $45.2 million and exceeded analysts’ forecast of $42.23 million. The company said the topline growth was driven by strong cannabis flower sales in Canada, Israel, and other countries.
Cronos posted a net income of $15.7 million, compared to $7.7 million in the prior year. The company said this increase was primarily supported by higher gross profit and other income. The EPS came in at $0.04, above the $0.02 that analysts expected.
Lord Jones, the company’s brand of CBD products that serves the premium consumer market, continued to expand its market share in Q1. In Canada’s chocolate cannabis edibles category, the brand held a 9.1% market share and ranked third in the country. Lord Jones also expanded into Israel’s medical cannabis market in Q1 and was met with strong demand for its premium flower strains.
Looking ahead, Cronos counts on its acquisition of CanAdelaar to accelerate its growth in Europe. It expects to close the acquisition in the summer of 2026.
Cronos Group Inc (NASDAQ:CRON) is a Canadian company that produces and sells a broad variety of cannabis and hemp-derived products. Its product portfolio includes dried flowers, pre-rolls, vapes, oils, and edibles, and these are sold under various brand names, such as Lord Jones.
While we acknowledge the potential of CRON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRON and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best CBD Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
